Literature DB >> 28235244

Increased frequency of multiple sclerosis among patients with bullous pemphigoid: a population-based cohort study on comorbidities anchored around the diagnosis of bullous pemphigoid.

L Kibsgaard1, M Rasmussen1, A Lamberg2, M Deleuran1, A B Olesen1, C Vestergaard1.   

Abstract

BACKGROUND: Bullous pemphigoid (BP) is a disease of the elderly and may be associated with neurological and cardiovascular diseases and diabetes. Mortality rates strongly exceed those of the background population.
OBJECTIVES: To investigate the frequency of comorbidities and their temporal relation to BP.
METHODS: A register-based matched-cohort study on all Danish patients with a hospital-based diagnosis of BP (n = 3281). The main outcomes were multiple sclerosis (MS), Parkinson disease (PD), Alzheimer disease (AD), stroke, diabetes types 1 and 2, malignancies, ischaemic heart disease (IHD), hypertension and eventually death.
RESULTS: At baseline, patients with BP had increased prevalences of MS [odds ratio (OR) 9·7, 95% confidence interval (CI) 6·0-15·6], PD (OR 4·2, 95% CI 3·1-5·8), AD (OR 2·6, 95% CI 1·8-3·5) and stroke (OR 2·7, 95% CI 2·4-2·9). Furthermore, malignancies, cardiovascular disease and diabetes were over-represented among patients with BP: type 1 diabetes (OR 3·1, 95% CI 2·5-3·8), type 2 diabetes (OR 2·3, 95% CI 2·0-2·6), malignancies (OR 1·3, 95% CI 1·1-1·4), IHD (OR 1·7, 95% CI 1·5-1·9) and hypertension (OR 2·0, 95% CI 1·8-2·2). During follow-up, the risk of MS was significantly higher among patients with BP [hazard ratio (HR) 9·4, 95% CI 4·9-18·0], even if events during the first year after diagnosis of BP were excluded (HR 5·1, 95% CI 2·3-11·3). Patients with BP had an average increased mortality rate of 2·04 (95% CI 1·96-2·13).
CONCLUSIONS: We discovered a significantly increased frequency of MS among patients with BP. At the time of diagnosis, patients with BP had an excessive number of comorbidities and an increased mortality rate over the following years.
© 2017 British Association of Dermatologists.

Entities:  

Mesh:

Year:  2017        PMID: 28235244     DOI: 10.1111/bjd.15405

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  10 in total

1.  Is there an association between dipeptidyl peptidase-4 inhibitors and autoimmune disease? A population-based study.

Authors:  Khalaf Kridin; Kyle Amber; Mogher Khamaisi; Doron Comaneshter; Erez Batat; Arnon D Cohen
Journal:  Immunol Res       Date:  2018-06       Impact factor: 2.829

2.  Dual inhibition of complement factor 5 and leukotriene B4 synergistically suppresses murine pemphigoid disease.

Authors:  Tanya Sezin; Sripriya Murthy; Claudia Attah; Malte Seutter; Maike M Holtsche; Christoph M Hammers; Enno Schmidt; Fibi Meshrkey; Sadegh Mousavi; Detlef Zillikens; Miles A Nunn; Christian D Sadik
Journal:  JCI Insight       Date:  2019-08-08

3.  Demographics and Autoantibody Profiles of Pemphigoid Patients with Underlying Neurologic Diseases.

Authors:  Kelly N Messingham; Adam D Miller; Nandakumar S Narayanan; Samuel J Connell; Janet A Fairley
Journal:  J Invest Dermatol       Date:  2019-03-12       Impact factor: 8.551

Review 4.  Comorbidities and Treatment Strategies in Bullous Pemphigoid: An Appraisal of the Existing Litterature.

Authors:  Rikke Bech; Line Kibsgaard; Christian Vestergaard
Journal:  Front Med (Lausanne)       Date:  2018-09-04

Review 5.  Bullous pemphigoid.

Authors:  Denise Miyamoto; Claudia Giuli Santi; Valéria Aoki; Celina Wakisaka Maruta
Journal:  An Bras Dermatol       Date:  2019-05-09       Impact factor: 1.896

Review 6.  Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.

Authors:  Kaisa Tasanen; Outi Varpuluoma; Wataru Nishie
Journal:  Front Immunol       Date:  2019-06-04       Impact factor: 8.786

Review 7.  Type XVII collagen: Relevance of distinct epitopes, complement-independent effects, and association with neurological disorders in pemphigoid disorders.

Authors:  Bianca Opelka; Enno Schmidt; Stephanie Goletz
Journal:  Front Immunol       Date:  2022-08-10       Impact factor: 8.786

Review 8.  Bullous Autoimmune Dermatoses–Clinical Features, Diagnostic Evaluation, and Treatment Options.

Authors:  Nina van Beek; Detlef Zillikens; Enno Schmidt
Journal:  Dtsch Arztebl Int       Date:  2021-06-18       Impact factor: 8.251

9.  Polymorphisms in the Mitochondrial Genome Are Associated With Bullous Pemphigoid in Germans.

Authors:  Juliane Russlies; Anke Fähnrich; Mareike Witte; Junping Yin; Sandrine Benoit; Regine Gläser; Claudia Günter; Rüdiger Eming; Jeanette Erdmann; Damian Gola; Yask Gupta; Maike Marleen Holtsche; Johannes S Kern; Inke R König; Dimitra Kiritsi; Wolfgang Lieb; Christian D Sadik; Miklós Sárdy; Franziska Schauer; Nina van Beek; Anke Weidinger; Margitta Worm; Detlef Zillikens; Enno Schmidt; Hauke Busch; Saleh M Ibrahim; Misa Hirose
Journal:  Front Immunol       Date:  2019-11-22       Impact factor: 7.561

Review 10.  Bullous Pemphigoid: Trigger and Predisposing Factors.

Authors:  Francesco Moro; Luca Fania; Jo Linda Maria Sinagra; Adele Salemme; Giovanni Di Zenzo
Journal:  Biomolecules       Date:  2020-10-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.